AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10712318 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (1 g every 12 h)
Number of subjects: 298
Study 10712318 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 298
Study 10712318 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 298
Study 8757574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl infusion
Number of subjects: 20
Study 8757574 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 1388662 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 108
Study 1388662 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 108
Study 3895289 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol (250 mg I/ml)
Number of subjects: 40
Study 3895289 — intervention group
Group type: COMPARATOR
Intervention: Ioxithalamate (250 mg I/ml)
Number of subjects: 40
Study 29531280 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Normative Feedback and Cognitive Bias Re‐training
Number of subjects: 672
Study 29531280 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Self‐monitoring and Feedback and Action Planning
Number of subjects: 672
Study 29531280 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Self‐monitoring and Feedback
Number of subjects: 672
Study 29531280 — intervention group
Group type: COMPARATOR
Intervention: Minimal version of app modules
Number of subjects: 672
Study 29424509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrodissection with epinephrine
Number of subjects: 44
Study 29424509 — intervention group
Group type: COMPARATOR
Intervention: Non-hydrodissection
Number of subjects: 44
Study 25064769 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 83
Study 25064769 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 83
Study 25064769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 25064769 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 83
Study 22379745 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg thrice daily plus omeprazole 20 mg twice daily
Number of subjects: 70
Study 22379745 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 70
Study 20058059 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Friendship Training (CFT)
Number of subjects: 0
Study 20058059 — intervention group
Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 0
Study 18502357 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol 300 mg orally 5 to 6 hours before surgery
Number of subjects: 66
Study 18502357 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 66
Study 16005690 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (10mg oral dose)
Number of subjects: 0
Study 12453950 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 390
Study 12453950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 10362210 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement (0.625 mg/day conjugated equine estrogens and 2.5 mg/day medroxyprogesterone acetate)
Number of subjects: 24
Study 10362210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/day)
Number of subjects: 24
Study 10362210 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement plus lovastatin
Number of subjects: 24
Study 10362210 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 24
Study 8964637 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Kd (gradual and constant elimination of K+)
Number of subjects: 0
Study 8964637 — intervention group
Group type: COMPARATOR
Intervention: Kd 2 mEq/l (standard potassium removal)
Number of subjects: 0
Study 2167702 — intervention group
Group type: COMPARATOR
Intervention: VAC (vincristine 1 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2)
Number of subjects: 80
Study 2167702 — intervention group
Group type: EXPERIMENTAL
Intervention: VACE (vincristine 1 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2, etoposide 80 mg/m2 for 3 days)
Number of subjects: 80
Study 7025960 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural evacuation
Number of subjects: 20
Study 7025960 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostomy irrigation
Number of subjects: 20
Study 7025960 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam enema
Number of subjects: 20
Study 7025960 — intervention group
Group type: COMPARATOR
Intervention: Colostomy irrigation and foam enema
Number of subjects: 20
Study 31182351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (target 1–2 mg)
Number of subjects: 39
Study 31182351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 31182351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 39
Study 29086911 — intervention group
Group type: COMPARATOR
Intervention: 50 μg phenylephrine
Number of subjects: 42
Study 29086911 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg ephedrine
Number of subjects: 42
Study 27550914 — intervention group
Group type: EXPERIMENTAL
Intervention: Less tight control (target diastolic 100 mm Hg)
Number of subjects: 981
Study 27550914 — intervention group
Group type: COMPARATOR
Intervention: Tight control (target diastolic 85 mm Hg)
Number of subjects: 981
Study 27550914 — intervention group
Group type: EXPERIMENTAL
Intervention: Less tight control
Number of subjects: 981
Study 27550914 — intervention group
Group type: COMPARATOR
Intervention: Tight control
Number of subjects: 981
Study 25017670 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic electrical epidural stimulation of the auditory cortex
Number of subjects: 9
Study 21818820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) chemoradiotherapy
Number of subjects: 71
Study 21818820 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) chemoradiotherapy
Number of subjects: 71
Study 20828648 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg)
Number of subjects: 18597
Study 20828648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18597
Study 18041059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 19818
Study 18041059 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 19818
Study 15807183 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump technique
Number of subjects: 60
Study 15807183 — intervention group
Group type: COMPARATOR
Intervention: On-pump technique
Number of subjects: 60
Study 12701762 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized children (n = 270)
Number of subjects: 270
Study 12701762 — intervention group
Group type: COMPARATOR
Intervention: Eligible children whose parents immediately refused participation (n = 243)
Number of subjects: 270
Study 12701762 — intervention group
Group type: COMPARATOR
Intervention: Eligible children whose parents were informed but did not consent (n = 406)
Number of subjects: 270
Study 10370919 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented feedback condition
Number of subjects: 91
Study 10370919 — intervention group
Group type: COMPARATOR
Intervention: Sensory feedback condition
Number of subjects: 91
Study 8957977 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 100
Study 8957977 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 100
Study 8957977 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 100
Study 8957977 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium-Mivacurium combination
Number of subjects: 100
Study 8957977 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium-Atracurium combination
Number of subjects: 100
Study 1677062 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 1817
Study 1677062 — intervention group
Group type: COMPARATOR
Intervention: Other vitamins (A,D,B1,B2,B6,C and nicotinamide)
Number of subjects: 1817
Study 1677062 — intervention group
Group type: COMPARATOR
Intervention: Both folic acid and other vitamins
Number of subjects: 1817
Study 1677062 — intervention group
Group type: COMPARATOR
Intervention: Neither folic acid nor other vitamins
Number of subjects: 1817
Study 6832465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol cream 0.25%
Number of subjects: 60
Study 6832465 — intervention group
Group type: COMPARATOR
Intervention: Dithranol stylus 0.2%
Number of subjects: 60
Study 6832465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol cream 0.25% and Dithranol stylus 0.2%
Number of subjects: 60
Study 30638644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil 0.7 μg/kg
Number of subjects: 60
Study 30638644 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 0.1 mg/kg
Number of subjects: 60
Study 28413993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus oral weight based ribavirin for 24 weeks
Number of subjects: 200
Study 28413993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus oral weight based ribavirin and a 180 mcg Peg‐INF alpha 2a subcutaneous injection weekly for 12 weeks
Number of subjects: 200
Study 25994549 — intervention group
Group type: EXPERIMENTAL
Intervention: FLU-v (500 μg) and the adjuvant
Number of subjects: 32
Study 25994549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adjuvant alone)
Number of subjects: 32
Study 25994549 — intervention group
Group type: EXPERIMENTAL
Intervention: FLU-v
Number of subjects: 32
Study 25994549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 24491069 — intervention group
Group type: EXPERIMENTAL
Intervention: FFT followed by CWD (FFT/CWD)
Number of subjects: 170
Study 24491069 — intervention group
Group type: EXPERIMENTAL
Intervention: CWD followed by FFT (CWD/FFT)
Number of subjects: 170
Study 24491069 — intervention group
Group type: COMPARATOR
Intervention: Coordinated FFT and CWD (CT)
Number of subjects: 170
Study 24491069 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment sequences
Number of subjects: 170
Study 23220732 — intervention group
Group type: EXPERIMENTAL
Intervention: GPO-VIR S30(®) [d4T plus lamivudine (3TC) plus nevirapine (NVP)] followed by GPO-VIR Z250(®) [AZT plus 3TC plus NVP]
Number of subjects: 150
Study 23220732 — intervention group
Group type: COMPARATOR
Intervention: GPO-VIR Z250(®) [AZT plus 3TC plus NVP]
Number of subjects: 150
Study 23220732 — intervention group
Group type: COMPARATOR
Intervention: TDF plus emtricitabine [FTC] plus NVP
Number of subjects: 150
Study 23220732 — intervention group
Group type: EXPERIMENTAL
Intervention: GPO-VIR S30(®) [d4T plus lamivudine (3TC) plus nevirapine (NVP)]
Number of subjects: 150
Study 19344076 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg daily for 12 weeks)
Number of subjects: 51
Study 17942579 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (250 mmol [5.75 g] per day)
Number of subjects: 24
Study 17942579 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture change (supine/seated)
Number of subjects: 24
Study 17942579 — intervention group
Group type: COMPARATOR
Intervention: Low sodium intake (70 mmol [1.61 g] per day)
Number of subjects: 24
Study 15260834 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-support program for families at risk
Number of subjects: 58
Study 15260834 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (assessments only)
Number of subjects: 58
Study 10811074 — intervention group
Group type: COMPARATOR
Intervention: Observation (no intervention) for 100 eyes
Number of subjects: 224
Study 8623970 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL bupivacaine 0.125% with 50 micrograms fentanyl followed by an infusion of 0.125% bupivacaine and 0.0002% fentanyl at 10 mL/h
Number of subjects: 28
Study 8623970 — intervention group
Group type: COMPARATOR
Intervention: 10 mL bupivacaine 0.125% followed by an infusion of 0.125% bupivacaine at 10 mL/h
Number of subjects: 28
Study 1611229 — intervention group
Group type: EXPERIMENTAL
Intervention: verlukast 8 mg
Number of subjects: 12
Study 1611229 — intervention group
Group type: EXPERIMENTAL
Intervention: verlukast 2 mg
Number of subjects: 12
Study 1611229 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6689975 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (5000 units two hours before operation and then 12-hourly for seven days)
Number of subjects: 95
Study 6689975 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (same regimen as heparin)
Number of subjects: 95
Study 31168921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0
Study 31168921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30317965 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate nonfunctional loading of implants (20 implants)
Number of subjects: 32
Study 30317965 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading protocol (19 implants)
Number of subjects: 32
Study 28076671 — intervention group
Group type: EXPERIMENTAL
Intervention: MOMCare (Brief Interpersonal Psychotherapy and/or antidepressants)
Number of subjects: 164
Study 28076671 — intervention group
Group type: COMPARATOR
Intervention: MSS-Plus (intensive public health Maternity Support Services)
Number of subjects: 164
Study 23006654 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care educational and reflective program based on the Burkhart/Hogan theory of spiritual care in nursing practice, incorporating face‐to‐face and on‐line components
Number of subjects: 59
Study 23006654 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care educational and reflective program
Number of subjects: 59
Study 19657182 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced tinnitus retraining therapy (TRT) including Jacobson's progressive muscle relaxation, physiotherapy, education via lectures, training of selective attention, and changes in appraisal, mental attitude, and behavior towards tinnitus.
Number of subjects: 0
Study 19657182 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (C)
Number of subjects: 0
Study 18286416 — intervention group
Group type: EXPERIMENTAL
Intervention: Change detection task with familiar scenes
Number of subjects: 0
Study 18286416 — intervention group
Group type: EXPERIMENTAL
Intervention: Change detection task with unfamiliar scenes
Number of subjects: 0
Study 16171663 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (group GA)
Number of subjects: 60
Study 16171663 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (group S)
Number of subjects: 60
Study 12589479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (acute effect)
Number of subjects: 10
Study 12589479 — intervention group
Group type: COMPARATOR
Intervention: Resting state (control)
Number of subjects: 10
Study 10788964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (0.2 mg.kg‐1)
Number of subjects: 94
Study 10788964 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (1.5 mg.kg‐1)
Number of subjects: 94
Study 8794502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate (FD) dosage reduction
Number of subjects: 37
Study 8794502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FD dosage reduction)
Number of subjects: 37
Study 8794502 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use group
Number of subjects: 37
Study 8794502 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use history
Number of subjects: 37
Study 8794502 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 37
Study 1524625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoretard (theophylline sustained-release preparation)
Number of subjects: 0
Study 1524625 — intervention group
Group type: COMPARATOR
Intervention: Diffumal (theophylline formulation of large consumption)
Number of subjects: 0
Study 2867023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg nocte
Number of subjects: 0
Study 2867023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 150 mg nocte
Number of subjects: 0
Study 2867023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30040033 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR‐RE (15 repetitions; 30% 1‐repetition maximum)
Number of subjects: 12
Study 30040033 — intervention group
Group type: COMPARATOR
Intervention: HI‐RE (80% 1‐repetition maximum to muscular failure)
Number of subjects: 12
Study 30040033 — intervention group
Group type: COMPARATOR
Intervention: LI‐RE (30% 1‐repetition maximum to muscular failure)
Number of subjects: 12
Study 29635534 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinoid moisturizer for prophylaxis (group P)
Number of subjects: 0
Study 29635534 — intervention group
Group type: COMPARATOR
Intervention: No moisturizer (group C)
Number of subjects: 0
Study 27009314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IV cannulation
Number of subjects: 61
Study 27009314 — intervention group
Group type: COMPARATOR
Intervention: Standard IV cannulation
Number of subjects: 61
Study 24479642 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised whole body vibration (WBV) training
Number of subjects: 54
Study 24479642 — intervention group
Group type: COMPARATOR
Intervention: Supervised multi-purpose exercise (MG)
Number of subjects: 54
Study 24479642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-purpose exercise with vibration (VMG)
Number of subjects: 54
Study 22333567 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal tibiofibular joint manipulation
Number of subjects: 43
Study 22333567 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal tibiofibular joint manipulation
Number of subjects: 43
Study 22333567 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 20347164 — intervention group
Group type: EXPERIMENTAL
Intervention: English version of the questionnaire
Number of subjects: 112
Study 20347164 — intervention group
Group type: EXPERIMENTAL
Intervention: French version of the questionnaire
Number of subjects: 112
Study 20347164 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest method for repeatability
Number of subjects: 112
Study 20347164 — intervention group
Group type: EXPERIMENTAL
Intervention: Validity assessment using on-farm observations
Number of subjects: 112
Study 18634442 — intervention group
Group type: EXPERIMENTAL
Intervention: Eviprostat tablet (6 tabs/day)
Number of subjects: 0
Study 18634442 — intervention group
Group type: EXPERIMENTAL
Intervention: EVI-F tablet (3 tabs/day)
Number of subjects: 0
Study 18634442 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 0
Study 17920256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg daily
Number of subjects: 472
Study 17920256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 15197114 — intervention group
Group type: EXPERIMENTAL
Intervention: A-line ARX index (AAI)
Number of subjects: 80
Study 15197114 — intervention group
Group type: COMPARATOR
Intervention: Bispectral index (BIS)
Number of subjects: 80
Study 11393438 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven assessor training
Number of subjects: 390
Study 11393438 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-driven assessor training
Number of subjects: 390
Study 11393438 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 390
Study 9589354 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk women with cytologic evidence of hyperplasia with or without atypia
Number of subjects: 254
Study 9589354 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk women with aneuploidy and overexpression of biomarkers (EGFR, p53)
Number of subjects: 254
Study 9589354 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk women with overexpression of ER and HER-2/neu
Number of subjects: 254
Study 9589354 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk women with normal cytology, epithelial hyperplasia, and hyperplasia with atypia
Number of subjects: 254
Study 9589354 — intervention group
Group type: EXPERIMENTAL
Intervention: Later detection of neoplastic conditions
Number of subjects: 254
Study 9589354 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of biomarker abnormalities in the 3-test battery
Number of subjects: 254
Study 7920882 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH/TRH stimulation tests in early follicular phase (EFP) and midluteal phase (MLP)
Number of subjects: 40
Study 2980548 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 100
Study 2980548 — intervention group
Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 100
Study 11480601 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat polyethylene insert (20 patients)
Number of subjects: 40
Study 11480601 — intervention group
Group type: COMPARATOR
Intervention: Concave polyethylene insert (20 patients)
Number of subjects: 40
Study 30711862 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic group (n=70)
Number of subjects: 140
Study 30711862 — intervention group
Group type: COMPARATOR
Intervention: Non-prebiotic group (n=70)
Number of subjects: 140
Study 30230531 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM intervention
Number of subjects: 92
Study 30230531 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 92
Study 27377782 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 20
Study 27377782 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 20
Study 24687229 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading comprehension strategy prompts integrated into digital text
Number of subjects: 15
Study 24687229 — intervention group
Group type: COMPARATOR
Intervention: No strategy prompt condition
Number of subjects: 15
Study 22229256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral letrozole (2.5 mg/day)
Number of subjects: 32
Study 22229256 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous gonadotropin-releasing hormone agonist (goserelin, 3.6 mg)
Number of subjects: 32